Hot Investor Mandate: VC Firm Seeks to Invest in Seed and Series A Technology-Enabled Healthcare Solutions With Focus on Europe-Based Companies  

14 Jul

The firm is an investment firm based in Europe that is developing a growth-focused investment strategy spanning life sciences and professional services. Founded by entrepreneurs with a successful track record of building and exiting a global technology company, the firm seeks to support innovation and long-term business growth through both early-stage venture investments and investments in established businesses. Within life sciences, the firm typically invests up to approximately €500K in Series A financings, with smaller investments at the Seed stage. The firm generally invests alongside other institutional investors through syndicated rounds. 

The firm invests in life science and healthcare companies developing innovative, technology-enabled solutions. Its primary focus is on businesses with scalable, service-oriented or technology-driven business models. While the firm is open to early-stage opportunities, it favors companies that have demonstrated a viable business model and a clear pathway toward commercial scale. 

From a company and management team perspective, the firm seeks founders with compelling value propositions that address meaningful unmet needs. The firm typically participates as a co-investor and provides value beyond capital through its entrepreneurial experience, deep industry expertise, and extensive professional network. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , , ,

Hot Investor Mandate: CVC Arm of Global Healthcare Business Makes Strategic Investments in Early-Stage Companies With Novel Therapeutic Approaches

14 Jul

The firm is the corporate venture capital arm of a global diversified healthcare and life sciences company with operations spanning food, healthcare, and advanced biological sciences. The firm invests strategically to support innovation across several long-term growth areas, with healthcare serving as a key focus. The firm primarily invests in Seed and Series A companies, committing up to approximately $4M in initial equity investments while reserving capital for follow-on financings. The firm invests globally, with a particular focus on opportunities in North America and Europe. 

The firm is primarily interested in early-stage biotechnology companies developing novel therapeutic platforms and differentiated treatment modalities. The firm is modality-agnostic and evaluates opportunities across small molecules, biologics, antibody-drug conjugates (ADCs), oligonucleotide therapeutics, cell therapies, and gene therapies. Platform technologies are of particular interest. The firm invests in companies from the preclinical through early clinical stages and is generally indication-agnostic, prioritizing highly innovative science with broad strategic potential. 

From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition. The firm places the greatest emphasis on novel science and differentiated technology. The firm generally prefers to participate as a co-investor and does not typically seek board representation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , , ,

Hot Investor Mandate: Western Europe VC Invests in Therapeutics, Medical Devices, and Diagnostics With a Focus on Pre-Clinical Technologies 

14 Jul

A venture capital firm with offices in Western Europe manages multiple life sciences investment funds focused on therapeutics, diagnostics, and medical devices. The firm specializes in early-stage healthcare investments and typically commits approximately €5–12M per portfolio company over multiple financing rounds. The firm primarily invests in European companies and is recognized for its hands-on investment approach and close collaboration with leading academic and clinical research institutions.  

The firm invests across therapeutics, diagnostics, and medical devices, with a primary focus on therapeutics. The firm is modality- and indication-agnostic, evaluating innovative technologies that are approximately 12 months or less from entering the clinic, as well as programs in Phase I and Phase II clinical development. In addition to traditional venture investing, the firm operates as a company builder, collaborating with academic institutions and industrial partners to identify promising scientific discoveries and establish new biotechnology companies.  

From a company and management team perspective, the firm seeks companies with differentiated science and clear value-creation pathways that can achieve strategic exit opportunities within approximately three to five years, often through partnerships or acquisitions by pharmaceutical companies. The firm works closely with founders, academic innovators, and industry partners to accelerate company formation, development, and commercialization. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , , ,

Hot Investor Mandate: Investment Firm and Venture Builder Seeks Innovative Therapeutics Addressing Unmet Medical Need Backed by Strong Data 

14 Jul

The firm is a therapeutics-focused venture builder and investment firm that partners with founders to discover, develop, and advance innovative medicines. The firm supports company creation through direct investments, focused spinouts, and de novo company formation. Combining venture investing with extensive drug discovery and development capabilities, the firm provides hands-on scientific, operational, and strategic support through a large multidisciplinary team of drug discovery experts, development professionals, and company builders. The firm invests through dedicated early- and clinical-stage funds, supporting programs from concept through key preclinical and clinical value-inflection milestones. 

The firm invests exclusively in therapeutics and is agnostic across modalities and disease areas. The firm supports both single-asset and platform companies and is willing to invest across a broad spectrum of maturity, ranging from well-defined scientific concepts to companies with substantial preclinical proof-of-concept or early clinical data. The firm focuses on advancing programs through major development milestones, including preclinical validation, development candidate selection, and clinical demonstration of therapeutic activity. 

From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition. Instead, the firm works as a highly collaborative partner, providing scientific, operational, and strategic guidance to help founders optimize development plans, generate high-quality data, and maximize long-term value creation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , , ,

RESI Boston 2026 Agenda Announced: Two Days of Investor Insights, Partnership Strategy, and Networking

14 Jul

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The agenda for RESI Boston 2026 is here, offering attendees an in-depth look at the conversations shaping the future of early-stage life science investment. Taking place September 22–23 at The Westin Copley Place in Boston, followed by virtual partnering days on September 25, 28, and 29, the expanded two-day in-person conference delivers more opportunities than ever to connect with investors, strategic partners, and industry leaders.

This year’s program reflects the evolving priorities of the healthcare investment ecosystem, with sessions designed to help innovators better understand today’s fundraising environment while building the relationships needed to move their companies forward.

Day one begins by exploring why Boston remains one of the world’s premier biotechnology hubs before examining key topics including partnering with health systems, how venture investors evaluate early-stage therapeutics, securing pharmaceutical partnerships, corporate venture capital strategies, digital health innovation, and the growing influence of family offices in healthcare investing. The day also features the Global Family Office Bioforum (GFOB), an invite-only private networking lunch that brings together select family office investors for high-value discussions and relationship building.

On day two, programming shifts toward emerging investment trends with sessions highlighting angel investing, women’s health, impact investing, and the increasingly important role of mission-driven capital. The conference concludes with two Reverse VC Pitch sessions, where investors take the stage to present directly to entrepreneurs, providing attendees with valuable insight into investment priorities, fund strategies, and what investors are actively seeking in new opportunities. The day also features the exclusive Global VC Connect Lunch, creating another dedicated opportunity for venture capital investors to build meaningful connections.

As always, RESI programming is designed to provide practical insights rather than theory. Whether attendees are preparing for their next fundraising round, pursuing strategic partnerships, or looking to better understand today’s investment landscape, every panel is curated to deliver actionable perspectives from experienced investors and industry leaders.

Combined with RESI’s partnering platform and three additional days of virtual meetings, the conference offers a comprehensive environment for companies seeking to advance fundraising and business development efforts.

Join the RESI Speaker Lineup

Are you an investor or strategic partner with valuable insights to share with early-stage life science companies? We are looking for dynamic speakers to join our RESI panels. Click here to submit your Speaker Interest Form today!

Registration is now open, with super early bird pricing currently available. Companies planning to attend are encouraged to register early to secure the best available rates and begin preparing for one of the most anticipated life science investment events of the year.

Register today and join the global life science investment community at RESI Boston 2026.

Register for RESI Boston

Tags: , , , , , , , , , , , , , , , , , , , ,

Save the Date – Global Family Office BioForum at RESI Boston – Where Active Investors Connect, Collaborate, and Co-Invest

14 Jul

September 22, 2026 | Westin Copley Place | RESI Boston

By Joey Wong, Director of Investor Research, Hong Kong BD, LSN

Joey-New-Headshot

Life Science Nation (LSN) is pleased to announce the formal program for the Global Family Office BioForum (GFOB) and invites qualified family office investors to participate in this exclusive gathering.

Held during the Redefining Early-Stage Investments (RESI) Conference on Tuesday, September 22, at the Westin Copley Place in Boston, GFOB provides a private, curated environment for family offices to:

  • Exchange strategies across asset classes and investment themes
  • Share deal flow insights and emerging biotech opportunities
  • Explore co-investment partnerships in early-stage therapeutics and healthcare innovation

In addition to the private luncheon and networking session, GFOB will feature a Family Office Investors Panel open to all RESI attendees. The panel will spotlight perspectives from seasoned family office investors who are actively deploying capital in the life sciences and healthcare sectors.

If you are a Family Office and would like to attend the Family Office BioForum Luncheon

RSVP for GFOB Here

Only active family office investors will be accepted.

Register for RESI Boston 2026
Secure your ticket and access over 500 investors across family offices, venture capital, pharma, and strategic partners.

Register for RESI Boston

Tags: , , , , ,

More Connections, Better Matches: Inside RESI San Diego’s 1,000+ Investor Meeting Success

14 Jul

By Sougato Das, President and COO, LSN

Sougato-Das

RESI San Diego was a powerhouse gathering of 300+ active early-stage life science investors including VCs, angels, family offices, CVCs, venture philanthropy, and pharma external innovation scouts across 10 distinct categories.

What made this event truly remarkable wasn’t just the sheer number of attendees, but their high level of engagement. Throughout the five-day hybrid conference, innovators and capital providers initiated thousands of high-value conversations, reinforcing why RESI remains a premier venue for early-stage companies seeking Seed, Series A, and Series B financing.

RESI San Diego: Partnering Success by the Numbers
The event saw incredible partnering activity, showcasing both high volume and improved precision:

  • 11,000+ Partnering requests submitted.
  • 1,400+ Accepted meetings.

This jump in efficiency reflects a growing emphasis on targeted outreach and thoughtful meeting selection, helping attendees spend less time chasing cold leads and more time speaking with organizations that closely match their technology and fundraising goals.

Furthermore, the hybrid format delivered maximum flexibility.

The RESI Differentiator: Why Our Matches are Stronger
Other industry conferences often suffer from half-empty investor profiles, making it incredibly difficult for fundraising startups to know whom to target. RESI is built differently.

  • Vetted, Highly-Detailed Profiles: Our dedicated Investor Research Team manually populates and verifies every single investor profile in the system. You get the exact detail you need to determine if an investor is a legitimate fit.
  • No “Undercover” Service Providers: Our team meticulously screens every participant to ensure that anyone registered as an investor is actually a legitimate capital provider ready to invest, not financial service providers in disguise.
  • High Visibility on Site: With investors easily identified by their red registration badges, initiating spontaneous, high-value conversations during in-person days was easier than ever.

Maintain Your Fundraising Momentum
Fundraising is a relationship-driven process. The strongest outcomes rarely come from a single meeting; they are built through multiple touchpoints over time. Participating in sequential RESI conferences allows you to strengthen existing relationships, introduce new data milestones, and refine your pitch.

Super Early Bird registration is now open for our upcoming landmark events:

  • RESI Boston (September 2026): Held during Biotech Week Boston, featuring 2 days of expanded in-person programming and 3 days of virtual partnering. (Save $300 if you register by this Friday, July 17!)
  • RESI JPM 2027 (January 2027): Returning to San Francisco during JPM Healthcare Week, the busiest week in healthcare venture capital. 2 days of live networking at the SF Marriott Marquis, followed by 3 days of global virtual partnering.

Lock in the lowest rates of the season today, secure your Super Early Bird pricing, and keep your fundraising momentum moving forward!

Register for RESI Boston Register for RESI JPM

Tags: , , , , , , , , , , , , , , , , , , , , , ,

← Older Entries